SpaceX IPO is the biggest IPO in stock market history. Join the conversation.Click here

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksCSRT.L Regulatory News (CSRT)

  • There is currently no data for CSRT

Voke® (DEV200) update

3 Jan 2017 07:00

RNS Number : 1264T
Consort Medical PLC
03 January 2017
 

 

Consort Medical plc

 

03 January 2017

 

Voke® (DEV200) update

 

Consort Medical plc ("Consort Medical") (LSE: CSRT) today announces that Nicovations Limited ("Nicovations"), a wholly-owned subsidiary of British American Tobacco plc ("BAT"), has served termination notices for all Supply Agreements with Bespak Europe Limited ("Bespak"), a Consort Medical subsidiary, for Voke®. Termination is effective immediately.

 

· Nicovations has terminated all supply agreements with Bespak for Voke, an MHRA approved nicotine inhaler for harm reduction in smoking

· Bespak remains in a constructive dialogue with Kind Consumer and Nicovations over the future of the Voke programme

· Voke is one of 16 programmes in Bespak's growing development pipeline and Consort Medical's Board at this time does not believe that the Termination materially impacts their expectations for the Group's underlying trading performance for the current financial year

 

Nicovations has terminated the Supply Agreements on the basis of lack of commercial launch of Voke before 31 December 2016, which is a termination right provided for in the Supply Agreements that Nicovation has chosen to invoke.

 

Voke, one of 16 programmes in Bespak's development pipeline, was designed by Kind Consumer, a developer of innovative, medically-authorised products, for licensing into consumer and pharmaceutical markets. The distribution rights to the product were licensed by Kind Consumer to Nicovations and, in relation to this licence agreement, in 2011 Nicovations also entered into separate Supply Agreements with Bespak. The agreements cover the build, manufacturing and supply of the filled Voke devices and associated valves.

 

Bespak remains in a constructive dialogue with Kind Consumer and Nicovations over the future supply of the Voke nicotine inhaler which addresses a fast growing multi-billion dollar market.

 

With a robust financial position and a strong development pipeline, the board of directors of Consort Medical at this time does not believe that the termination of the Supply Agreements materially impacts their expectations for Consort Medical Group's underlying trading performance for the current financial year ending 30 April 2017.

 

Jonathan Glenn, Chief Executive Officer of Consort Medical, commented:

 

"Our recent interim financial results highlighted the underlying strength in Bespak and Aesica and the momentum emanating from the growing and diverse pipeline portfolio of significant development programmes. Therefore, while we are naturally disappointed in the loss of the Supply Agreements for Voke to Nicovations, we continue our dialogue with Kind Consumer and with Nicovations on the future of the programme and we remain highly confident in the robustness of the remainder of our business and our prospects for the future".

 

- Ends -

 

 

Enquiries:

 

Consort Medical

Tel: +44 1442 867920

Jonathan Glenn - Chief Executive Officer

FTI Consulting

Tel: +44 20 3727 1000

Ben Atwell / Simon Conway

 

 

Notes:

 

Market Abuse Regulations (MAR)

This announcement contains inside information.

 

About Consort Medical

 

Consort Medical plc is a leading, global, single source drug and delivery device company (CDMO). We are at the leading edge of innovation and we are committed to investing in patient, clinician and customer driven innovation to create new treatments, new markets and new opportunities.

 

Our businesses

 

Bespak is a global market leader in the manufacture of drug delivery devices for pharmaceutical partner companies, including respiratory, nasal, and injectable products, and the manufacture of devices for the point of care diagnostics market. www.bespak.com.

 

Aesica is a leading provider of finished dose and active pharmaceutical ingredient (API) development and manufacturing services to pharmaceutical partners. www.aesica-pharma.com.

 

We employ more than 2000 people globally of which 1400 are located in the UK. We have UK facilities in King's Lynn, Cambridge, Nelson, Milton Keynes, Cramlington, Queenborough and Hemel Hempstead, German facilities in Monheim and Zwickau and a facility in Pianezza, Italy. Consort Medical is a public company quoted on the premium list of the London Stock Exchange (LSE: CSRT). www.consortmedical.com.

 

This information is provided by RNS
The company news service from the London Stock Exchange
 
END
 
 
MSCBTMBTMBIMTTR
Date   Source Headline
25th Jul 20197:00 amRNSDirector/PDMR Shareholding
16th Jul 20193:49 pmRNSHolding(s) in Company
15th Jul 20197:00 amRNSIncident at the Aesica Cramlington API Facility
13th Jun 20197:00 amRNSFull Year results
29th May 20198:37 amRNSHolding(s) in Company
28th May 201912:50 pmRNSHolding(s) in Company
21st May 20194:30 pmRNSNotice of Results
15th Apr 20199:21 amRNSBlock listing Interim Review
1st Apr 20199:00 amRNSTotal Voting Rights
19th Mar 20199:14 amRNSHolding(s) in Company
7th Feb 20191:28 pmRNSAGM Voting Update - Director Declaration
31st Jan 20197:00 amRNSDEV610: FDA approval for Mylan's generic Advair
15th Jan 20193:03 pmRNSHolding(s) in Company
2nd Jan 20199:07 amRNSTotal Voting Rights
21st Dec 20187:00 amRNSClosure of American Depositary Receipt Programme
20th Dec 20188:56 amRNSHolding(s) in Company
11th Dec 20189:11 amRNSDirector/PDMR Shareholding
7th Dec 20189:16 amRNSHolding(s) in Company
6th Dec 20185:18 pmRNSDirector/PDMR Shareholding
4th Dec 20187:00 amRNSInterim Results
3rd Dec 20188:47 amRNSTotal Voting Rights
8th Nov 20183:49 pmRNSDirector/PDMR Shareholding
7th Nov 20182:49 pmRNSHolding(s) in Company
6th Nov 201812:30 pmRNSNotice of Results
6th Nov 20187:00 amRNSDirectorate Change
31st Oct 201811:17 amRNSDirector/PDMR Shareholding
15th Oct 20189:17 amRNSBlock listing Interim Review
10th Oct 20182:24 pmRNSDirector/PDMR Shareholding
9th Oct 201810:46 amRNSDirector/PDMR Shareholding
2nd Oct 201812:57 pmRNSDirector/PDMR Shareholding
1st Oct 20189:08 amRNSTotal Voting Rights
10th Sep 20187:00 amRNSDirector/PDMR Shareholding
10th Sep 20187:00 amRNSConsort Signs Development Agreements with Opiant
6th Sep 20183:47 pmRNSDirector/PDMR Shareholding
5th Sep 20184:41 pmRNSResult of AGM
3rd Sep 20188:20 amRNSTotal Voting Rights
23rd Aug 20184:51 pmRNSHolding(s) in Company
22nd Aug 20185:21 pmRNSDirector/PDMR Shareholding
9th Aug 20187:24 amRNSForm 8.5 (EPT/RI) Consort Medical Plc
9th Aug 20187:20 amRNSForm 8.5 (EPT/RI) - Carclo Plc
9th Aug 20187:00 amRNSDirector/PDMR Shareholding
8th Aug 20182:58 pmRNSForm 8.3 - Consort Medical Plc
7th Aug 20183:20 pmRNSForm 8.3 - Consort Medical plc
7th Aug 201812:00 pmRNSForm 8.5 (EPT/RI) Consort Medical Plc
7th Aug 201812:00 pmRNSForm 8.5 (EPT/RI) - Carclo Plc
7th Aug 20189:43 amRNSStatement re withdrawal of Consort Medical plc
7th Aug 20188:23 amRNSConsort Medical No Intention to Bid for Carclo plc
6th Aug 20183:11 pmRNSForm 8.3 - Consort Medical PLC
6th Aug 20189:28 amRNSForm 8.3 - Consort Medical plc
3rd Aug 20183:08 pmRNSForm 8.3 - Consort Medical PLC

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.